JP Morgan analyst Paul Coster downgrades Itron (NASDAQ:ITRI) from Neutral to Underweight and lowers the price target from $53 to $50.
Immutep Quarterly Activities Report Q1 FY24; With A Cash And Cash Equivalent Balance As At 30 September 2023 Of Approximately $110.1M
FINANCIAL SUMMARYImmutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24), while strategically investing into clinical trial programs for efti.With a cash and cash
